These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24292030)

  • 1. Liposomal amphotericin B versus pentavalent antimony salts for visceral Leishmania in children.
    Apa H; Devrim İ; Bayram N; Deveci R; Demir-Özek G; Cartı ÖU
    Turk J Pediatr; 2013; 55(4):378-83. PubMed ID: 24292030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
    Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of visceral leishmaniasis in children].
    Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
    Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
    Morizot G; Jouffroy R; Faye A; Chabert P; Belhouari K; Calin R; Charlier C; Miailhes P; Siriez JY; Mouri O; Yera H; Gilquin J; Tubiana R; Lanternier F; Mamzer MF; Legendre C; Peyramond D; Caumes E; Lortholary O; Buffet P
    PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004304. PubMed ID: 26735920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis.
    Santos MA; Marques RC; Farias CA; Vasconcelos DM; Stewart JM; Costa DL; Costa CH
    Rev Soc Bras Med Trop; 2002; 35(6):629-33. PubMed ID: 12612746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
    Dilber E; Erduran E; Işik Y
    Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of infantile visceral leishmaniasis].
    Minodier P; Faraut-Gambarelli F; Piarroux R; Gire C; Garnier JM; Dumon H
    Arch Pediatr; 1999 Jan; 6(1):59-66. PubMed ID: 9974099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric visceral leishmaniasis in southern France.
    Minodier P; Piarroux R; Garnier JM; Unal D; Perrimond H; Dumon H
    Pediatr Infect Dis J; 1998 Aug; 17(8):701-4. PubMed ID: 9726344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
    Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
    AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Visceral leishmaniasis: new drugs].
    Minodier P; Robert S; Retornaz K; Garnier JM
    Arch Pediatr; 2003 Dec; 10 Suppl 5():550s-556s. PubMed ID: 15022780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful treatment of cutaneous leishmaniasis with amphotericin B; a case of unresponsive to pentavalent antimony therapy].
    Yeşilova Y; Turan E; Sürücü HA; Aksoy M; Özbilgin A
    Turkiye Parazitol Derg; 2015 Mar; 39(1):63-5. PubMed ID: 25917587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of leishmaniasis in HIV-positive patients.
    Laguna F
    Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():135-42. PubMed ID: 14678640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
    Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
    Minodier P; Retornaz K; Horelt A; Garnier JM
    Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma.
    Badaro R; Falcoff E; Badaro FS; Carvalho EM; Pedral-Sampaio D; Barral A; Carvalho JS; Barral-Netto M; Brandely M; Silva L
    N Engl J Med; 1990 Jan; 322(1):16-21. PubMed ID: 2104665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of treatment regimens of kala-azar based on culture & sensitivity of amastigotes to sodium antimony gluconate.
    Thakur CP; Thakur S; Narayan S; Sinha A
    Indian J Med Res; 2008 Jun; 127(6):582-8. PubMed ID: 18765878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
    Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
    Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Mediterranean visceral leishmaniasis.
    Gradoni L; Bryceson A; Desjeux P
    Bull World Health Organ; 1995; 73(2):191-7. PubMed ID: 7743590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cumulative cardiac toxicity of sodium stibogluconate and amphotericin B in treatment of kala-azar.
    Maheshwari A; Seth A; Kaur S; Aneja S; Rath B; Basu S; Patel R; Dutta AK
    Pediatr Infect Dis J; 2011 Feb; 30(2):180-1. PubMed ID: 20823781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.